Chester County News and Community Website
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) is targeting a fourth-quarter 2026 regulatory filing for its experimental type 1 diabetes cell therapy after reaching general alignment with the U.S. …
Century Targets FDA Filing for Diabetes Cell Therapy Read More PHILADELPHIA, PA — Century Therapeutics (NASDAQ: IPSC) will present new data on its experimental type 1 diabetes cell therapy at two scientific conferences this fall, a step that comes as …
Century Therapeutics Advances Diabetes Program With Conference Talks Read More PHILADELPHIA, PA — Century Therapeutics (Nasdaq: IPSC) reported new preclinical data supporting its experimental type 1 diabetes therapy CNTY-813, as the biotechnology company works toward a planned Investigational New Drug …
Century Therapeutics Advances Diabetes Cell Therapy Toward 2026 FDA Filing Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (Nasdaq: IPSC) said it remains on track to seek regulatory clearance next year for its experimental type 1 diabetes cell therapy as the company …
Century Advances Diabetes Cell Therapy Toward Human Trials Read More PHILADELPHIA, PA — Century Therapeutics Inc. (Nasdaq: IPSC) reported its financial results for 2025 and outlined progress across its pipeline of stem cell-derived therapies, including plans to submit a regulatory …
Century Therapeutics Reports 2025 Results, Advances Cell Therapy Pipeline Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has appointed Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its board of directors, strengthening governance and strategic oversight as the …
Century Therapeutics Adds Veteran Deal-Makers to Board as Pipeline Nears Clinic Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has unveiled its first program targeting Type 1 diabetes, introducing an engineered cell therapy designed to restore natural insulin production without the …
Century Therapeutics Debuts Immune-Evasive Cell Therapy Aiming to Transform Type 1 Diabetes Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) reported third quarter 2025 results and announced a major expansion of its pipeline with a new induced pluripotent stem cell (iPSC)-derived beta …
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) announced that Chief Scientific Officer Chad Cowan, Ph.D., will deliver a presentation at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October …
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference Read More PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) announced that CEO Brent Pfeiffenberger, Pharm.D., will deliver a company presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The event …
Century Therapeutics to Present at Global Investment Conference Read More